Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
Frontiers in Immunology
|
August 28, 2020
FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
Daniel P Hart
Journal of Thrombosis and Haemostasis : JTH
|
August 26, 2021
Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach" - Will we ever be able to avoid inhibitor formation in hemophilia A?
Daniel P Hart
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 31, 2019
Safety and efficacy of emicizumab and other novel agents in newborns and infants
Glenn F Pierce, Daniel P Hart, Radoslaw Kaczmarek, et al.
Hematology (Amsterdam, Netherlands)
|
November 13, 2019
Re-personalization and stratification of hemophilia care in an evolving treatment landscape
Daniel P Hart, Craig M Kessler, Lou Aledort
British Journal of Haematology
|
May 10, 2014
Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A
Paul Batty, Sean Platton, Louise Bowles, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 24, 2021
The factor VIII treatment history of non-severe hemophilia A-Response from original authors Abdi et al
Fabienne R Kloosterman, Amal Abdi, Samantha C Gouw, et al.
Plos One
|
January 20, 2017
Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients
Sandra B van Os, Nick A Troop, Keith R Sullivan, et al.
Therapeutic Advances in Hematology
|
April 28, 2023
Considerations for shared decision management in previously untreated patients with hemophilia A or B
Jan Astermark, Jan Blatný, Christoph Königs, et al.
Expert Opinion on Biological Therapy
|
August 21, 2007
T-cell receptor gene therapy for cancer: the progress to date and future objectives
Sharyn Thomas, Daniel P Hart, Shao-An Xue, et al.
British Journal of Haematology
|
September 23, 2014
A large-scale computational study of inhibitor risk in non-severe haemophilia A
Adrian J Shepherd, Stuart Skelton, Clare E Sansom, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
Frontiers in Immunology
|
August 28, 2020
FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
Daniel P Hart
Journal of Thrombosis and Haemostasis : JTH
|
August 26, 2021
Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach" - Will we ever be able to avoid inhibitor formation in hemophilia A?
Daniel P Hart
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 31, 2019
Safety and efficacy of emicizumab and other novel agents in newborns and infants
Glenn F Pierce, Daniel P Hart, Radoslaw Kaczmarek, et al.
Hematology (Amsterdam, Netherlands)
|
November 13, 2019
Re-personalization and stratification of hemophilia care in an evolving treatment landscape
Daniel P Hart, Craig M Kessler, Lou Aledort
British Journal of Haematology
|
May 10, 2014
Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A
Paul Batty, Sean Platton, Louise Bowles, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 24, 2021
The factor VIII treatment history of non-severe hemophilia A-Response from original authors Abdi et al
Fabienne R Kloosterman, Amal Abdi, Samantha C Gouw, et al.
Plos One
|
January 20, 2017
Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients
Sandra B van Os, Nick A Troop, Keith R Sullivan, et al.
Therapeutic Advances in Hematology
|
April 28, 2023
Considerations for shared decision management in previously untreated patients with hemophilia A or B
Jan Astermark, Jan Blatný, Christoph Königs, et al.
Expert Opinion on Biological Therapy
|
August 21, 2007
T-cell receptor gene therapy for cancer: the progress to date and future objectives
Sharyn Thomas, Daniel P Hart, Shao-An Xue, et al.
British Journal of Haematology
|
September 23, 2014
A large-scale computational study of inhibitor risk in non-severe haemophilia A
Adrian J Shepherd, Stuart Skelton, Clare E Sansom, et al.
Page
of 5